Direkt zum Inhalt
Merck
  • Histamine in the locus coeruleus promotes descending noradrenergic inhibition of neuropathic hypersensitivity.

Histamine in the locus coeruleus promotes descending noradrenergic inhibition of neuropathic hypersensitivity.

Pharmacological research (2014-10-12)
Hong Wei, Cong-Yu Jin, Hanna Viisanen, Hao-Jun You, Antti Pertovaara
ZUSAMMENFASSUNG

Among brain structures receiving efferent projections from the histaminergic tuberomammillary nucleus is the pontine locus coeruleus (LC) involved in descending noradrenergic control of pain. Here we studied whether histamine in the LC is involved in descending regulation of neuropathic hypersensitivity. Peripheral neuropathy was induced by unilateral spinal nerve ligation in the rat with a chronic intracerebral and intrathecal catheter for drug administrations. Mechanical hypersensitivity in the injured limb was assessed by monofilaments. Heat nociception was assessed by determining radiant heat-induced paw flick. Histamine in the LC produced a dose-related (1-10μg) mechanical antihypersensitivity effect (maximum effect at 15min and duration of effect 30min), without influence on heat nociception. Pretreatment of LC with zolantidine (histamine H2 receptor antagonist), but not with pyrilamine (histamine H1 receptor antagonist), and spinal administration of atipamezole (an α2-adrenoceptor antagonist), prazosine (an α1-adrenoceptor antagonist) or bicuculline (a GABAA receptor antagonist) attenuated the antihypersensitivity effect of histamine. The histamine-induced antihypersensitivity effect was also reduced by pretreatment of LC with fadolmidine, an α2-adrenoceptor agonist inducing autoinhibition of noradrenergic cell bodies. Zolantidine or pyrilamine alone in the LC failed to influence pain behavior, while A-960656 (histamine H3 receptor antagonist) suppressed hypersensitivity. A plausible explanation for these findings is that histamine, due to excitatory action mediated by the histamine H2 receptor on noradrenergic cell bodies, promotes descending spinal α1/2-adrenoceptor-mediated inhibition of neuropathic hypersensitivity. Blocking the autoinhibitory histamine H3 receptor on histaminergic nerve terminals in the LC facilitates release of histamine and thereby, increases descending noradrenergic pain inhibition.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Lidocain, powder
Sigma-Aldrich
L-Lysin -monohydrochlorid, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Histamin -dihydrochlorid, ≥99% (TLC), powder
Sigma-Aldrich
Histamin, ≥97.0%
USP
Lidocain, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Histamin -dihydrochlorid, ≥99.0% (AT)
Sigma-Aldrich
Cimetidin
Sigma-Aldrich
Lidocain, analytical standard
Sigma-Aldrich
L-Lysin -monohydrochlorid, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Mepyramin -maleat (Salz)
Supelco
Lidocain, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Histamin, analytical standard
USP
Cimetidin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
(+)-Bicucullin, ≥97.0% (TLC)
Supelco
L-Lysin -monohydrochlorid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Lysin -monohydrochlorid, BioUltra, ≥99.5% (AT)
Lysin -hydrochlorid, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Lysin -monohydrochlorid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Cimetidin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Pyrilamin-Maleat, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Lysin-hydrochlorid -Lösung, 100 mM amino acid in 0.1 M HCl, analytical standard
Lidocain, European Pharmacopoeia (EP) Reference Standard
Histamin -dihydrochlorid, European Pharmacopoeia (EP) Reference Standard
Mepyraminmaleat, European Pharmacopoeia (EP) Reference Standard
Cimetidin, European Pharmacopoeia (EP) Reference Standard
Cimetidin für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Cimetidin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard